Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23567314 | 1.00 | MAPT (0.33) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567219 | 1.00 | MAPT (0.33) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567235 | 1.00 | MAPT (0.33) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567248 | 1.00 | MAPT (0.33) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567313 | 1.00 | MAPT (0.33) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567273 | 0.98 | USP2 (0.31) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567315 | 0.92 | HTT (0.42) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567220 | 0.92 | MAPT (0.38) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567279 | 0.92 | HTT (0.42) | MAPTHTTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23567308 | 0.92 | HTT (0.42) | MAPTHTTCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024359-B | Process for preparing alkoxymethyl alkynyl ether compounds having terminal triple bonds | 信越化学工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| EP-3842406-B1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | SHINETSU CHEMICAL CO (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-11384041-B2 | Process for preparing an alkoxymethyl alkynyl ether compound having a terminal triple bond | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-07-12 | — | — | US | disclosed |
| US-20210198172-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3842406-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-06-30 | — | — | EP | disclosed |
| CN-113024359-A | Method for producing alkoxymethyl alkynyl ether compounds having terminal triple bond | 信越化学工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198172-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | CBR3, CBR1, AOC2 | MAPT 4691/4885HTT 3236/4885CYP1A2 275/4885 |
| US-11384041-B2 | Process for preparing an alkoxymethyl alkynyl ether compound having a terminal triple bond | CBR3, CBR1, AOC2 | MAPT 4691/4885HTT 3236/4885CYP1A2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.